Table 2.
Anti-VEGF Injection History Per Patient During the Study
| Patient | Rx Arm | Study Eye |
Prestudy | In-Study | Prestudy Median/Mean |
Study Median/Mean |
Lesion Type |
|---|---|---|---|---|---|---|---|
| 3 | Daclizumab | OS | 0.6 | 0.34 | 0.725 | 0.420 | Occult |
| 9 | Daclizumab | OD | 0.74 | 0.34 | 0.805 | 0.503 | Occult |
| 13 | Daclizumab | OS | 1.17 | 0.83 | — | — | Occult |
| 8 | Daclizumab | OD | 0.71 | 0.5 | — | — | Occult |
| 2 | Infliximab | OD | 0.67 | 0.5 | 0.700 | 0.830 | Min classic |
| 6 | Infliximab | OS | 0.93 | 0.83 | 0.767 | 0.777 | Occult |
| 10 | Infliximab | OS | 0.7 | 1 | — | — | Classic |
| 4 | Observation | OS | 0.5 | 0.83 | 0.670 | 0.830 | Occult |
| 5 | Observation | OD | 0.75 | 0.5 | 0.640 | 0.777 | Min classic |
| 11 | Observation | OD | 0.67 | 1 | — | — | Classic |
| 1 | Rapamycin | OS | 1 | 0.5 | 0.67 | 0.34 | Occult |
| 7 | Rapamycin | OD | 0.44 | 0.29 | 0.703 | 0.377 | Classic |
| 12 | Rapamycin | OD | 0.67 | 0.34 | — | — | Classic |
Rx, therapeutic arm; OD, right eye; OS, left eye; Min, minimally.